Anti-CD3 MUC1 bispecific antibody-PD 1 inhibitor activated CIK therapy

Drug Profile

Anti-CD3 MUC1 bispecific antibody-PD 1 inhibitor activated CIK therapy

Alternative Names: Activated CIK - anti-CD3-MUC1 bispecific antibody - Benhealth; Anti-CD3-MUC1 bispecific antibody; Cytokine induced killer cell therapy - Benhealth; PD-1 inhibitor activated CIK; PD-1 inhibitor activated CIK cells - Benhealth; PD-1 inhibitor activated cytokine induced killer cell therapy

Latest Information Update: 16 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Benhealth Biopharmaceutical
  • Class Bispecific antibodies; Cell therapies; Drug conjugates
  • Mechanism of Action CD3 antigen inhibitors; Mucin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 01 May 2017 Phase-II clinical trials in Liver cancer (Late-stage disease) in China (unspecified route) (NCT03146637)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top